Published On:November 23, 2016, 11:55 am
Western blot imaging system is a unique technique in the life science lab where the proteins are separated based on their molecular weight using gel electrophoresis. Chemiluminescence is the most popular western blot detection method due to its superior level of sensitivity, and imaging systems pitched towards the use along with the technique are available to additionally optimize the pace, stability of the signal, sensitivity, and user-friendliness. During the process at the end of electrophoresis, the estranged molecules are transferred to a second matrix which comprises of nitrocellulose membrane or polyvinylidene difluoride (PVDF). To avoid any kind of nonspecific adhering of protein antibodies to the surface of the membrane, it is arrested with a particular mechanism. There are two kinds of western blotting techniques – direct detection and indirect detection methods. The direct method possesses qualities such as swift effect owing to the presence of one antibody and primary antibodies. However, the disadvantage associated with this method is that it consists of lessened immunoreactivity of key antibody termed as primary antibody, low flexibility, non cost-efficient. Additionally, the indirect variant has advantages such as potential options of labeled secondary antibodies, secondary antibody amplifying signal, and primary antibody immunoreactivity stays unaltered by labeling.
The global western blot imagers industry was valued at US $510.1 million in 2014 and it garnered more than 25% of the global molecular diagnostics market. By the end of 2021, this industry’s market is projected to probably reach US $725.0 million, while growing at a CAGR of 5.4% during the forecast period owing to the increased occurrence of HIV and constant research in proteomics segment. More percentage of expenditure and increasing investment in the R&D by several biotechnology and pharmaceutical companies are two key factors contributing towards the lucrative growth of the western blot imagers market. The outgrowth of substitute method for the detection of protein and a superior price of products will probably hinder the market growth of global western blot imagers industry. A few prime trends in this industry include implementation of the automated enhanced techniques, innovation of latest and new imaging software for analysis of western blot results, and steady investment in R&D and an upsurge in acquisitions and mergers.
To Request Sample Copy of This Report: http://www.qyresearchgroups.com/request-sample/138573
Geographically, the global western blot imagers industry has been segmented into Europe, North America, Asia Pacific and the Rest of the World. As of 2016, North America garners the highest market share of the western blot imagers, followed by Asia Pacific and Europe. Nevertheless, Asia Pacific market is predicted to grow at the most rapid CAGR over the forecast period owing to the development of bioclusters in India and China, increasing biotechnology and pharmaceutical segment in Japan, budding funding for agricultural research in India, increasing diagnosis and expenditure for HIV in Australia, Chinese governments’ keen interest in biotechnology and biomedical industry, increased occurrence of HSV in South East Asia, together are propelling the growth of the western blot imagers industry market in the Asia Pacific region. Some of the major market players of the global western blot imagers industry are Thermo Fisher Scientific, Inc. (U.S.), LI-COR Biosciences (U.S.), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Advansta, Inc. (U.S.), Bio-Techne Corporation (U.S.), Cell Signaling Technology, Inc. (U.S.), Merck KGaA (Germany), and GE Healthcare (U.S.).
We will be happy to help you find what you need. Please write to us: